Evidence map›Paper›PMID 37943386›Full record

ArticleDigestive diseases and sciences2024

Features of Metabolite Changes in Disease Evolution in Cholecystolithiasis.

Kun Zhang, Yongzheng Wang, Xiaoxuan Cui, Wei Wang, Yuliang Li

Open access · hybridAbstract read
In one paragraph

Article in Digestive diseases and sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.3field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Kun ZhangShanghai Biotree Biotech Co. Ltd., Shanghai, China.ORCID http://orcid.org/0009-0009-5404-7772
Yongzheng WangDepartment of Interventional, The Second Hospital of Shandong University, Shandong, 250033, China.
Xiaoxuan CuiShanghai Biotree Biotech Co. Ltd., Shanghai, China.
Wei WangDepartment of Interventional, The Second Hospital of Shandong University, Shandong, 250033, China. wwei0125@126.com.
Yuliang LiDepartment of Interventional, The Second Hospital of Shandong University, Shandong, 250033, China.
Second Hospital of Shandong University · CN

Funding

National Natural Science Foundation of China (12171285&11971269), Program for Integrated Traditional Chinese and Western Medicine in Shandong Province of China YXH2019ZXY007
6 · The paper itself

Abstract

backgroundCholecystolithiasis is defined as a disease caused by complex and changeable factors. Advanced age, female sex, and a hypercaloric diet rich in carbohydrates and poor in fiber, together with obesity and genetic factors, are the main factors that may predispose people to choledocholithiasis. However, serum biomarkers for the rapid diagnosis of choledocholithiasis remain unclear.

aimsThis study was designed to explore the pathogenesis of cholecystolithiasis and identify the possible metabolic and lipidomic biomarkers for the diagnosis of the disease.

methodsUsing UHPLC-MS/MS and GC-MS, we detected the serum of 28 cholecystolithiasis patients and 19 controls. Statistical analysis of multiple variables included Principal Component Analysis (PCA). Visualization of differential metabolites was performed using volcano plots. The screened differential metabolites were further analyzed using clustering heatmaps. The quality of the model was assessed using random forests.

resultsIn this study, dramatically altered lipid homeostasis was detected in cholecystolithiasis group. In addition, the levels of short-chain fatty acids and amino acids were noticeably changed in patients with cholecystolithiasis. They detected higher levels of FFA.18.1, FFA.20.1, LPC16.0, and LPC20.1, but lower levels of 1-Methyl-L-histidine and 4-Hydroxyproline. In addition, glycine and L-Tyrosine were higher in choledocholithiasis group. Analyses of metabolic serum in affected patients have the potential to develop an integrated metabolite-based biomarker model that can facilitate the early diagnosis and treatment of the disease.

conclusionOur results highlight the value of integrating lipid, amino acid, and short-chain fatty acid to explore the pathophysiology of cholecystolithiasis disease, and consequently, improve clinical decision-making.

Indexed as

CholecystolithiasisCholedocholithiasisBiomarkersFemaleHumansLipidsTandem Mass SpectrometryBiomarkersLipidsAmino acidCholecystolithiasisFree fatty acid (FFA)LipidLysophosphatidylcholine (LPC)Short-chain fatty acid

Identifiers

PMID37943386
PMCPMC10787879
OpenAlexW4388539781

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.